Skip to main content

Table 1 Correlation between clinicopathological features and SAM68 expression in MIBC patients

From: Utility of SAM68 in the progression and prognosis for bladder cancer

Characteristics n SAM68 χ2testP-value n SAM68 χ2testP-value
Low High Nucleus Cytoplasm Nucleus and cytoplasm co-expression
Age (years) <60 63 32(50.8) 31(49.2) 0.292 62 25(40.3) 12(19.4) 25(40.3) 0.362
≥60 66 27(40.9) 39 (59.1) 61 18(29.5) 11 (18.0) 32 (52.5)
Gender Male 116 55(47.4) 61 (52.6) 0.380 110 40(36.4) 21 (19.1) 49 (44.5) 0.497
Female 13 4(30.8) 9 (69.2) 13 3(23.1) 2 (15.4) 8 (61.5)
pT stage T2 80 43(53.8) 37(46.3) 0.028 77 30(39.0) 18(23.4) 29(37.7) 0.035
T3~4 49 16(32.7) 33(67.3) 46 13(28.3) 5(10.9) 28(60.9)
pN stage N 111 55(49.5) 56(50.5) 0.041 105 39(37.1) 22(21.0) 44(41.9) 0.050
N+ 11 4(22.2) 14(77.8) 18 4(6.3) 1(5.6) 13(72.2)
Grade Low 32 12(37.5) 20(62.5) 0.312 31 11(35.5) 4(12.9) 16(51.6) 0.608
High 97 47(48.5) 50(51.5) 92 32(34.8) 19(20.7) 41(44.6)
Smoking history Yes 68 29(42.6) 39(57.4) 0.483 65 23(35.4) 12(18.5) 30(46.2) 0.994
No 61 30(49.2) 31(50.8) 58 20(34.5) 11(19.0) 27(46.6)
Gross hematuria Yes 102 43(42.2) 59(57.8) 0.132 97 32(33.0) 19(49.5) 46(47.4) 0.664
No 27 16(59.3) 11(40.7) 26 11(42.3) 4(15.4) 11(42.3)
UIS Yes 18 8(44.4) 10(55.6) 1.000 17 5(29.4) 2(11.8) 10(58.8) 0.511
No 111 51(45.9) 60(54.1) 106 38(35.8) 21(19.8) 47(44.3)
Tumor multiplicity Yes 70 34(48.6) 36(51.4) 0.595 66 18(27.3) 16(24.2) 32(48.5) 0.087
No 59 25(42.4) 34(57.6) 57 25(43.9) 7(12.3) 25(43.9)
Adjuvant chemotherapy Yes 39 13(33.3) 26(66.7) 0.083 37 13(35.1) 4(10.8) 20(54.1) 0.295
No 90 46(51.1) 44(48.9) 86 30(34.9) 19(22.1) 37(43.0)
Tumor recurrence Yes 35 9(25.7) 26(74.3) 0.006 32 6(18.8) 5(15.6) 21(65.6) 0.031
No 94 50(53.2) 44(46.8) 91 37(40.7) 18(19.8) 36(39.6)
  1. MIBC: muscle invasive bladder cancer; UIS: urinary irritation symptoms.